Pharmaxis cuts 30% of jobs following FDA's Bronchitol rejection
This article was originally published in Scrip
Executive Summary
Pharmaxis said it will cut expenses by 29% and reduce its employee headcount by 30% two months after the US FDA rejected the Australian company's dry-powder mannitol medicine developed to improve pulmonary function in patients with cystic fibrosis (CF).